Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Berenberg analyst Luisa Hector lowered the firm’s price target on Merck (MRK) to $115 from $125 and keeps a Buy rating on the shares. Merck ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Glancy Prongay & Murray LLP reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the class action filed on ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Shares in Rapid Micro Biosystems jumped Friday in premarket trading after it said it signed an agreement with Merck's life science business to distribute its microbiology testing platform. Shares ...